University of Kentucky
UKnowledge

Theses and Dissertations--Dietetics and Human Nutrition

Dietetics and Human Nutrition

2020

CARDIAC EFFECTS OF OBESITY DURING PREGNANCY IN C57BL/6J MICE

Kayla Lynn Dudick

University of Kentucky, k.dudick@gmail.com

Author ORCID Identifier:

<https://orcid.org/0000-0001-6583-192X>

Digital Object Identifier: <https://doi.org/10.13023/etd.2020.431>

[Right click to open a feedback form in a new tab to let us know how this document benefits you.](#)

Recommended Citation

Dudick, Kayla Lynn, "CARDIAC EFFECTS OF OBESITY DURING PREGNANCY IN C57BL/6J MICE" (2020).
Theses and Dissertations--Dietetics and Human Nutrition. 81.
https://uknowledge.uky.edu/foodsci_etds/81

This Master's Thesis is brought to you for free and open access by the Dietetics and Human Nutrition at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Dietetics and Human Nutrition by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File.

I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless an embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

REVIEW, APPROVAL AND ACCEPTANCE

The document mentioned above has been reviewed and accepted by the student's advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student's thesis including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Kayla Lynn Dudick, Student

Dr. Robin Shoemaker, Major Professor

Dr. Dawn Brewer, Director of Graduate Studies

CARDIAC EFFECTS OF OBESITY DURING
PREGNANCY IN C57BL/6J MICE

THESIS

A thesis submitted in partial fulfillment of the
requirements for the degree of Master of Science
in Nutrition and Food Systems in the College of
Agriculture, Food and Environment at the University
of Kentucky

By

Kayla Lynn Dudick

Lexington, Kentucky

Director: Dr. Robin Shoemaker, Associate Professor of Dietetics and Human Nutrition

Lexington, Kentucky

2020

Copyright © Kayla Lynn Dudick 2020

<https://orcid.org/0000-0001-6583-192x>

ABSTRACT OF THESIS

CARDIAC EFFECTS OF OBESITY DURING PREGNANCY IN C57BL/6J MICE

Objective: Pregnancy requires profound cardiac and metabolic adaptation. Left ventricular (LV) mass is increased in response to pregnancy, but is not associated with cardiac damage. In contrast, obesity-mediated cardiac hypertrophy is pathological. Data from animal studies indicate dietary fatty acid composition may have a protective effect during states of extreme cardiac physiological adaptation. In contrast, aberrant cardiac metabolism is a hallmark of disease. Over a third of reproductive-age women in the United States are obese, but there is a paucity of data describing the effect of obesity on maternal cardiac adaptation to pregnancy. The objective of this study was to determine the effects of high-fat feeding during pregnancy on cardiac hypertrophy and metabolism in a mouse model of diet-induced obesity.

Methods/Results: Female C57BL/6J mice (8 weeks old) were fed a high fat (HF; 60% kcal from fat) or a control low fat (LF; 10% kcal from fat) diet for 8 weeks, then were either crossed with male mice to become pregnant (P) or remained non-pregnant (NP) controls. At gestational day 18, cardiac function was quantified by echocardiography in LF- and HF-fed P and NP females. On gestational 19 day, mice were euthanized for tissue collection. HF-fed females had significantly increased body weight compared to LF-fed controls, and body weight was increased in P compared to NP mice. In response to pregnancy, LF-, but not HF-fed, mice had significantly increased LV mass ($P<0.01$). In contrast, HF-fed pregnant mice had increased relative wall thickness (RWT: $[2 \times \text{LV posterior wall thickness} / \text{LV end-diastolic diameter}]$) compared to LF-fed pregnant mice. We quantified mRNA abundance of genes regulating fatty acid oxidation utilization in left ventricles of LF- and HF-fed pregnant and non-pregnant mice using Nanostring nCounter Analysis system. *Acaa2*, *Acox1*, and *Acadl* (genes regulated long-chain fatty acid oxidation) and *Cpt1b* (regulating fatty acid transport into the mitochondria) were upregulated with both HF-feeding and pregnancy. In contrast,

Ehhadh, a gene regulating production of medium chain fatty acids during fatty acid oxidation, was increased in pregnant mice, but only in the LF mice, and the expression was significantly reduced in HF- compared to LF-fed pregnant mice.

Conclusions: Physiological cardiac hypertrophy in response to pregnancy was observed in LF-fed, but not HF-fed mice. In contrast, HF-fed pregnant mice had increased RWT compared to LF-fed pregnant mice. While fatty acid utilization was increased with HF-feeding and pregnancy, the expression of *Ehhadh* was reduced in HF- compared to LF-fed mice. Medium chain fatty acids are demonstrated in the literature to be protective against pathological cardiac remodeling in experimental animals. Taken together, these data suggest obesity may impair protective fatty acid utilization pathways in pregnancy to promote adverse cardiac remodeling.

KEYWORDS: Pregnancy, CVD, Obesity, Cardiac Metabolism, Remodeling

Kayla Lynn Dudick
(*Name of Student*)

11/13/2020
Date

CARDIAC EFFECTS OF OBESITY DURING PREGNANCY
IN C57BL/6J MICE

By
Kayla Lynn Dudick

Robin Shoemaker, PhD

Director of Thesis

Dawn Brewer, PhD, RD, LD

Director of Graduate Studies

11/13/2020

Date

TABLE OF CONTENTS

LIST OF TABLES	v
LIST OF FIGURES	vi
CHAPTER 1. INTRODUCTION	1
1.1 <i>Background</i>	1
1.2 <i>Problem Statement</i>	2
1.3 <i>Overall hypothesis</i>	2
1.4 <i>Research Questions</i>	2
1.5 <i>Impact</i>	2
CHAPTER 2. LITERATURE REVIEW	4
2.1 <i>Cardiac physiology of pregnancy</i>	4
2.1.1 Hemodynamics (the flow of blood through the vessels and organs in the body)	4
2.1.2 Cardiac morphology (size, shape, and geometry)	5
2.1.3 Reverse Adaptation	6
2.2 <i>Epidemiology of pregnancy history and maternal heart health</i>	6
2.2.1 Sex differences in CVD	6
2.2.2 Pregnancy complications are associated with maternal risk for CVD	7
2.3 <i>Obesity and pregnancy complications</i>	8
2.4 <i>Cardiac effects of obesity</i>	9
2.4.1 Obesity augments traditional risk factors	9
2.4.2 Obesity is an independent risk factor for CVD	10
2.4.3 Cardiac effects of obesity during pregnancy	10
2.5 <i>Cardiac metabolism</i>	11
2.5.1 Overview of cardiac metabolism	11
2.5.2 Altered cardiac metabolism hallmark of disease states	12
2.5.3 Cardiac metabolism during pregnancy	13
CHAPTER 3. METHODS	16
3.1 <i>Experimental animals and study design</i>	16
3.2 <i>Echocardiography</i>	17
3.3 <i>Tissue RNA extraction and gene expression analysis</i>	17

3.4	<i>Statistical analysis</i>	18
CHAPTER 4. RESULTS		20
4.1	<i>HF-feeding increases body weight and fat mass</i>	20
4.2	<i>HF-feeding reduces litter size</i>	20
4.3	<i>HF-feeding increases heart weight and LV mass, but is not augmented with pregnancy</i>	20
4.4	<i>Wall thickness is increased in HF-compared to LF-fed pregnant mice</i>	21
4.5	<i>Analysis of genes regulating metabolism in hearts</i>	21
CHAPTER 5. DISCUSSION		28
5.1	<i>Limitations and Future Studies</i>	32
5.2	<i>Public Health/Clinical Significance</i>	33
CHAPTER 6. CONCLUSION		35
REFERENCES		36
VITA		41

LIST OF TABLES

Table 1: Litter size and pup/placental weights from LF- or HF-fed pregnant female mice.	23
Table 2: Heart weights of LF- and HF-fed pregnant and non-pregnant female mice.....	23

LIST OF FIGURES

Figure 1: “Pregnancy is a “stress test” that can reveal subclinical trajectories and identify new opportunities for chronic disease prevention”.....	15
Figure 2: Overview of cardiac metabolism.....	15
Figure 3. Experimental Design	19
Figure 4: Weight gain from baseline to gestational day 19	24
Figure 5: LV mass and RWT	25
Figure 6: Flow chart of cardiac genes measured using Nanostring significantly changed using 2-way ANOVA by either diet or pregnancy.	26
Figure 7: mRNA abundance of fatty acid utilization genes in pregnant and non-pregnant mice fed a LF or HF diet.	27

CHAPTER 1. INTRODUCTION

1.1 Background

Increasing evidence suggests that pregnancy is a sensitive window where adverse effects on cardiovascular function may permanently alter maternal risk for cardiovascular diseases (CVD) ². Epidemiology studies demonstrate that women with a history of pregnancy complications, such as gestational hypertension or diabetes, preterm delivery, or intrauterine growth restriction are at greater risk for mortality from CVD ³. Rodent studies support that the profound cardiovascular adaptations during pregnancy may serve as a type of “stress test”, to unmask cardiovascular vulnerabilities ⁴. These data suggest pregnancy complications are a sex-specific risk factor for CVD. Obesity is strongly associated with pregnancy complications, with a nearly stepwise increase in the incidence of preterm birth, gestational diabetes, hypertensive disorders, and other high-risk conditions with increasing category of body mass index (BMI) ⁵. This is concerning as the prevalence of both obesity and CVD are rising in women of reproductive age in the United States ⁶.

Pregnancy induces many structural and functional changes in the cardiovascular system to accommodate the growing uteroplacental unit. One such change is cardiac hypertrophy, or enlargement of the heart in response to increased metabolic demands. Cardiac hypertrophy with pregnancy is assumed to be transient, and is not associated with cardiac damage ⁷. In contrast, cardiac hypertrophy occurring in response to obesity is pathological, and a prognostic indicator for CVD ⁸. Despite the known associations between obesity, pregnancy complications, and maternal CVD, there is limited research

describing how obesity modulates cardiac hypertrophy of pregnancy. This is important, as adverse cardiac effects during pregnancy may drive future maternal risk for CVD.

1.2 Problem Statement

Women with a history of obesity-mediated pregnancy complications are at a greater risk of CVD. However, mechanisms linking pregnancy complications and CVD are unknown. Both obesity and pregnancy independently promote cardiac hypertrophy and are associated with changes in cardiac metabolism. It is not known how obesity during pregnancy modulates cardiac hypertrophy and energy metabolism.

1.3 Overall hypothesis

The overall hypothesis of this research project is that obesity during pregnancy promotes adverse cardiac remodeling associated with altered cardiac metabolism.

1.4 Research Questions

1. Does obesity promote altered cardiac hypertrophy during pregnancy in mice?
2. What is the effect of obesity during pregnancy on the expression of genes that regulate cardiac metabolism in mice?

1.5 Impact

If a woman is going to make a lifestyle change, she is more likely to do so while pregnant. This is a crucial time when healthcare professionals need evidence-based

nutritional strategies that can be tailored to accommodate individual nutritional needs and provide sustainable modifications. By providing individualized, sustainable nutritional therapies, women may reduce their risk or progression of obesity-mediated pregnancy complications and/or CVD.

CHAPTER 2. LITERATURE REVIEW

2.1 Cardiac physiology of pregnancy

Pregnancy is a dynamic process, requiring immense physiological adaptation of the cardiovascular system. This includes changes in blood volume, heart function, and changes in properties and function of blood vessels. These changes are necessary for accommodating the growing fetoplacental unit, and to meet the increased metabolic demands of the mother. Insufficient ability of the mother's body to adapt to these cardiovascular changes can adversely affect the health of both the mother and the fetus. In fact, the cardiovascular demands of pregnancy can sometimes reveal otherwise silent cardiovascular pathologies. This is why pregnancy is often referred to as "nature's stress test"².

2.1.1 Hemodynamics (the flow of blood through the vessels and organs in the body)

One of the biggest changes during pregnancy is the increase in blood volume. Blood volume increases early in the first trimester, and steadily increases throughout gestation. The total increase in blood volume varies widely, between 20% to an astonishing 100% of pre-pregnancy volume, usually approximated to be about a 45% increase⁷. The vascular system accommodates this via vasodilation (widening of vessels) and an overall decrease of about 35% to 40% in systemic vascular resistance (resistance of vessels to blood flow). Vascular resistance is lowest in the first trimester, accommodating development of the placenta, followed by a slight increase in the end of the second trimester, and remains steady for the remainder of pregnancy. Blood pressure

decreases accordingly, being the lowest in the first trimester, then returning to near pre-pregnancy levels by the third trimester ⁷.

The increase in blood volume translates to increased stroke volume (the volume of blood pumped through the heart with each beat). Accordingly, cardiac output (the volume of blood pumped through the heart each minute) also increases up to 45% during pregnancy, where cardiac output is determined by multiplying the stroke volume by the heart rate. In summary, Cardiac output is increased by an astounding 30-50%, and peripheral vascular resistance and blood pressure decrease by roughly 20% during pregnancy⁷.

2.1.2 Cardiac morphology (size, shape, and geometry)

Cardiac morphology is significantly altered during pregnancy. Cardiac morphology can be assessed via echocardiography, a noninvasive technique that uses ultrasound waves to make images of the heart. Pregnancy is well known to cause cardiac hypertrophy, an enlargement of the heart and ventricles, in response to metabolic demands, including increased blood volume. Cardiac hypertrophy is represented by the mass of the left ventricle (LV). LV mass is estimated to increase by about 40% by the third trimester of pregnancy ⁷. The physiological cardiac hypertrophy of pregnancy is associated with changes in shape and geometry, as well, collectively termed cardiac remodeling. Characterization of cardiac remodeling in pregnancy is not very well defined. A recent study in humans reported increased chamber size with wall thinning, termed “eccentric” remodeling ⁹. Changes in cardiac remodeling during pregnancy are of interest, as adverse remodeling can be a prognostic indicator of future CVD. This will be discussed further below.

2.1.3 Reverse Adaptation

Literature in humans suggests cardiac changes during pregnancy return to pre-pregnancy values, within a year ⁷. However, these studies are historical, and few studies have characterized cardiac function and structure postpartum using modern technology. Studies in healthy animals suggest that hemodynamics and cardiac morphology return to pre-pregnancy values about 7 days postpartum ¹⁰. However, recent rodent studies demonstrate that factors such as age and health status (i.e. obesity) may be detrimental to reverse cardiac adaptation postpartum ^{11,12}. This is important, as a growing body of literature suggests that factors impacting cardiovascular function during pregnancy have a lasting impact on maternal cardiovascular function.

2.2 Epidemiology of pregnancy history and maternal heart health

2.2.1 Sex differences in CVD

Cardiovascular disease is the number one cause of death in both men and women in the United States, but the disease manifests differently in women compared to men ¹³. For example, women are more likely to develop certain types of heart disease, such as stroke, left ventricular (LV) diastolic dysfunction, and heart failure with preserved ejection fraction (HFpEF) ¹⁴. Women also have a more steeply increasing risk with age compared to men ⁶. Only in the last decade have mechanisms contributing to sex differences in CVD become a major research focus. Contributing to the lack of understanding of CVD in women is the fact that females have traditionally been marginalized in human and animal studies ¹⁵.

Recent studies defining the role of sex hormones on cardiovascular function have contributed to significant advancements in explaining sex differences in type, timing, and mortality of CVD¹³. Research examining sex disparities between men and women in terms of pathology and physiology has revealed that women are more likely to experience endothelial and microvascular dysfunctions related to coronary artery disease compared to men¹⁶. These differences might be attributed to estrogen, which is reported to have protective effects on vascular and endothelial function, as well as metabolism and adiposity¹⁷. However, discrepancies exist in findings from randomized-controlled trials designed to test protective effects of female sex hormones against CVDs¹⁸. In the Women's Health Initiative (WHI), hormone replacement therapy in postmenopausal women actually contributed to increased risk for CVD in some women¹⁹, suggesting that sex hormones alone cannot be solely responsible for protective effects against CVD in women. In addition to sex hormones, sex chromosome complement also contributes to development of CVD, such as aneurysms¹³. These findings indicate that other sex-specific factors also contribute to differential cardiovascular function between males and females. The experience of pregnancy is one of the most profound physiological differences between males and females, requiring extensive cardiovascular adaptation.

To improve heart health in women, it is essential to define how cardiovascular stress during pregnancy affects future maternal cardiovascular function.

2.2.2 Pregnancy complications are associated with maternal risk for CVD

Pregnancy complications, such as gestational hypertension or diabetes, preterm delivery, or intrauterine growth restriction (IUGR) are associated with mortality from cardiovascular disease (CVD)³. Results from several large cohort studies demonstrate

that women with a history of gestational hypertension and related conditions, such as preeclampsia, have an increased risk for developing CVDs like hypertension, ischemic heart disease, stroke, and death due to CVD even decades after delivery ²⁰. As a group, complicated pregnancies are characterized by inflammation, vascular dysfunction, thrombosis, and insulin resistance; physiologic pathways which are common to CVD. These data suggest that adverse physiology of a woman's reproductive history may serve as a predictor for chronic disease (see Figure 1) ². It is not clear whether pregnancy is a "stress test" that reveals latent cardiovascular abnormalities, or if adverse effects on the cardiovascular system during pregnancy can permanently alter the trajectory of maternal heart health (or both).

2.3 Obesity and pregnancy complications

Obesity is the most common medical condition during pregnancy that affects maternal and fetal health ⁵. According to the CDC, the prevalence of obesity in the United States is increasing in women of reproductive age, with approximately 55% of women aged 20-39 years old having a body mass index (BMI) of greater than 25, and approximately 31% having a BMI over 30 ²¹. Maternal obesity has both short-term and long-term health consequences for mother and offspring. Obesity during pregnancy is associated with fertility problems, metabolic derangements, hypertensive disorders (such as preeclampsia), premature delivery, cesarean delivery, impaired fetal growth or macrosomia, and stillbirth ²².

Epidemiological data worldwide has linked maternal obesity to increased risk for metabolic and cardiovascular disease in offspring ²³. *However, mechanisms directly linking maternal obesity to subsequent cardiovascular disease are not known.*

2.4 Cardiac effects of obesity

2.4.1 Obesity augments traditional risk factors

It is well established that obesity augments cardiovascular risk factors, such as blood pressure, blood lipid levels, and the development of metabolic syndrome. In men and women, obesity is a primary contributor to the development of hypertension ²⁴. High blood pressure is a significant predictor for CV events ²⁵. While the overall worldwide prevalence of hypertension is greater in men, with increasing age (and menopause), the incidence of hypertension in women rises ⁶. Given that the prevalence of obesity is greater in women (at all ages) ²¹, the overall burden of obesity-associated hypertension may actually be greater in women than men.

Obesity contributes to dyslipidemia by increasing blood triglyceride and Free Fatty Acids (FFA) levels ²⁶. Consequences of this include perturbed lipoprotein metabolism, causing the formation of atherogenic lipoprotein particles, as well as free fatty acid-mediated insulin resistance ²⁷. Dyslipidemia increases the risk for CVD, such as atherosclerosis and coronary heart disease ²⁸.

Excess adipose tissue with obesity, especially visceral or abdominal adipose stores, also indirectly contributes to increased cardiovascular risk through release of inflammatory mediators. Adipose tissue secretes a number of adipokines that contribute to immune function and metabolism, and a pathological consequence of excess adipose

mass is increased secretion of adipokines and other pro-inflammatory factors, such as TNF- α , IL-6, and MCP-1 ²⁹. These factors can have diverse adverse effects including impaired endothelial function and increased insulin resistance ³⁰.

2.4.2 Obesity is an independent risk factor for CVD

In addition to augmenting cardiovascular risk factors, such as hypertension and type 2 diabetes, obesity is an independent risk factor for cardiovascular disease ³¹.

Obesity is associated with global longitudinal strain, and both impaired systolic and diastolic function ³². In response to increased blood volume and stroke volume (SV), mean arterial pressure and ventricular filling pressures can become elevated ^{33 34}.

Obesity and excess adiposity are directly associated with cardiac hypertrophy and remodeling ³⁵, and geometric changes are further augmented with increasing blood pressure ³⁶. Interestingly, although absolute LV mass is greater in men, when normalized for body size, the effect of obesity to increase LV mass is reported to be greater in women versus men ³⁷. Further, a direct association is reported between LV mass and body fat percentage, especially visceral adipose tissue ³⁸. The proportion of body fat is generally greater in women compared to men. Taken together, these data suggest that women may be particularly susceptible to obesity-mediated alterations in cardiac morphology.

2.4.3 Cardiac effects of obesity during pregnancy

It is fairly well-documented that obese women have increased blood pressure compared to non-obese women during pregnancy ^{39 40}. Further, obesity is a risk factor for hypertensive disorders of pregnancy, such as preeclampsia ⁴¹. What is less clear is the direct effect of obesity on cardiac structure and function during pregnancy, as well as, the

long-term implications. In a study comparing obese versus non-obese women at 36 weeks gestation, blood pressure and LV mass were increased with obesity, but no differences were observed with respect to CO or ventricular function ⁴⁰. In contrast, a serial study over trimesters in 16 obese and 17 non-obese pregnancies reported differences in SV and contractility in obese women ⁴². Interestingly, the difference was most striking with respect to the change in function throughout gestation. SV was greater in obese versus non-obese women in the first trimester, however non-obese women exhibited an increase in SV and CO throughout gestation, which was not observed in obese women. A similar trend was observed in indices of contractility, with some measures of contractility actually decreasing in obese women in the third trimester. The authors concluded that obesity was associated with impaired LV contractile response. Using speckle tracking in conjunction with echocardiography, Buddeberg et al recently reported diastolic dysfunction and LV global longitudinal strain in obese pregnant women at term compared with non-obese controls ⁴³. These studies provide evidence that obesity during pregnancy can adversely modulate cardiac function. However, the long-term consequences of these alterations on cardiovascular health are not known.

2.5 Cardiac metabolism

2.5.1 Overview of cardiac metabolism

The heart is a biological pump that converts chemical substrates into mechanical energy ⁴⁴. The heart primarily consumes carbohydrates (10-30%) and fats (60-90%) while using oxygen to drive oxidative phosphorylation to generate ATP from ADP ⁴⁵. ATP is

then used to drive contractile function (beating), to perfuse the body with blood and nutrients. Energy consumption of the human heart is about 10% of whole-body fuel consumption. The heart is described as a metabolic omnivore and has incredible flexibility to utilize a variety of substrates in the presence of oxygen to generate ATP. Energy producing substrates include triacylglycerols, fatty acids, glucose, glycogen, lactate, pyruvate, the ketone bodies acetoacetate and β -hydroxybutyrate, and amino acids, especially leucine, isoleucine, and valine (branched-chain amino acids) ⁴⁵. These substrates enter the Krebs cycle primarily as acetyl-CoA, or other intermediates of the Krebs cycle, for production of reducing equivalents (e.g., NADH and FADH₂ are a couple), which deliver electrons to the electron-transport chain in the mitochondria. The resulting generation of a proton gradient drives the formation of ATP. In an anerobic state, the heart can also utilize lactate (via degradation of glucose) and succinate (via degradation of some amino acids). See Figure 2 for schematic of cardiac metabolism.

2.5.2 Altered cardiac metabolism hallmark of disease states

The heart has the capacity to adapt to an altered metabolic state by selecting available substrates for the most effective generation of ATP. This metabolic flexibility is lost during heart failure, and pathologic states directly influencing substrate availability (e.g. obesity, diabetes) can further contribute to impaired cardiac function ⁴⁶. It is well-known that diabetes is associated with increased fatty acid utilization and decreased glucose utilization ⁴⁷. Likewise, obesity results in increased fatty acid utilization and reduced glucose oxidation rates ⁴⁸. This is likely due to substrate availability, as obesity is associated with increased levels of circulating fatty acids and triglycerides. Conversely, the

reduction in glucose utilization is likely due to the Randle effect, where increased utilization of fatty acids has an inhibitory effect on glucose metabolism ⁴⁷.

Changes in substrate metabolism precede changes in function and may be the first indication of functional abnormalities. Studies in humans and animals demonstrate that prolonged increase in fatty acid utilization results in increased myocardial oxygen consumption, i.e. increased oxidative phosphorylation, and reduced cardiac efficiency ⁴⁹. Despite obesity being associated with an increase in the number of mitochondria, studies in *ob/ob* mice (a genetic mouse model of obesity) reveal that mitochondria from obese hearts have deficits in oxidative capacity ⁵⁰. This dysfunctional condition is called oxidative uncoupling, where oxygen consumption is increased, but a proportional increase in ATP production is not observed ⁵¹. This is a potential mechanism by which obesity promotes impaired cardiac function. Increased fatty acid uptake and oxidation promote the formation of damaging reactive oxygen species (ROS) from mitochondrial complexes, but energy production declines ⁵¹. The potential consequence for reduced cardiac efficiency is a limitation in cardiac reserve, which may be worsened in the face of hemodynamic stressors, such as cardiac hypertrophy and increased blood pressure.

2.5.3 Cardiac metabolism during pregnancy

As described above, pregnancy is a form of cardiac stress. Notably, LV mass increases by up to 50%, which requires energy. Interestingly, while cardiac work increases by 20-30% during pregnancy, cardiac oxygen consumption is only increased by approximately 15% ⁵². Thus, cardiac efficiency is increased during pregnancy. There is not much known about cardiac metabolism during pregnancy. Studies from rats indicate a progressive decline in glucose utilization, with up to a 70% reduction by late pregnancy

⁵³. Studies in dogs demonstrate a large increase in fatty acid oxidation, indicating that the ATP production in the heart during late pregnancy is almost exclusively due to increased utilization of fats ⁵⁴.

There are no studies in humans or animals describing the combined effects of obesity and pregnancy on cardiac metabolic function. The present study will directly fill that gap.

Figure 1: “Pregnancy is a “stress test” that can reveal subclinical trajectories and identify new opportunities for chronic disease prevention”.

From Breathing life into the
lifecourse approach: Pregnancy
history and cardiovascular disease in
women, Rich-Edwards et al, 2010 ².

Figure 2: Overview of cardiac metabolism

Overview of cardiac metabolism, from Myocardial Substrate Metabolism in the Normal and Failing Heart, Stanley et al, 2005 ¹.

CHAPTER 3. METHODS

3.1 Experimental animals and study design

All studies using mice were approved by an Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky and were conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Female C57BL/6J mice (8 weeks of age; Jackson Laboratory, Bar Harbor, ME, stock # 000664) were randomly assigned to receive, ad libitum, either a high fat (HF; 60% kcal from fat; D12492, Research Diets, New Brunswick, NJ) or a control low fat (LF, 10% kcal from fat; D12450B, Research Diets Inc) diet for 8 weeks (n=30 mice/diet group) (see Figure 3 for experimental design). The control LF diet was purified and ingredient-matched to the HF diet, and the fat source for both diets was soybean oil and lard (where lard comprises the excess fat in the HF diet). The energy densities of the LF and HF diet are 3.82 and 5.21 kcal/g, respectively. Body weight was quantified weekly throughout the study using an Ohaus portable digital scale.

At 8 weeks of diet feeding, all female mice were placed in a cage with male mice of the same strain and diet. After 2 days, females were removed from the males, and placed in single housing for the duration of the study.

Echocardiography was performed on LF- and HF-fed female pregnant and non-pregnant mice 16 days following removal from male cage. The following day, mice were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.) for exsanguination and tissue harvest. Fetuses and placentas were dissected and weighed. Tissues were snap frozen in liquid nitrogen and stored at -80°C until analysis. Tissues taken included: heart, liver, kidney, spleen, para-uterine fat, and subcutaneous fat.

3.2 Echocardiography

Echocardiography was performed on isoflurane-anesthetized mice as described previously¹². Day 16 was chosen, because normal mouse gestation is 20 days or the equivalent of the third trimester in humans. Briefly, mice were anesthetized using 2-4% isoflurane (at effect) according to their size and then transferred to a heated platform (37°C) with 1-2% isoflurane supplied via nose cone. Hair on the chest region was shaved and removed, and electrode cream was applied on the front and hind limbs before being secured with electrical tape to electrodes on the platform. Respiration rate (RR) and heart rate (HR) were monitored and adjusted to a certain range across all mice by titrating isoflurane levels. An RR of 100 times/min and HR of 400 beats/min were targeted. Images of the cross-sectional view of the left ventricle (LV) at the papillary muscle-level in parasternal short-axis (PSAX) view were obtained in M-mode using an M550 transducer under the cardiology package on a Vevo 3100. Images were analyzed using VevoLab software using LV trace methodology.

3.3 Tissue RNA extraction and gene expression analysis

Approximately 20 mg of the left ventricle was used to extract total RNA using the Maxwell RSC (Promega, Madison, WI). RNA concentrations and quality were determined using a Nanodrop 2000. All samples had a 260/280 and 260/230 ratios > 2.0. The NanoString nCounter Metabolic Pathways Panel and nCounter Analysis System (NanoString Technologies, Seattle, WA) was used to quantify mRNA abundance of 768 genes regulating metabolism. As previously described¹², the Nanostring nCounter gene expression system is a multiplexed assay that uses a combination of unique capture

probes and color-coded reporter probes to capture and count individual mRNA transcripts with high sensitivity and tight correlation to real-time PCR 55. Fifty nanograms of RNA of each sample was hybridized to the target-specific capture and reporter probes in the CodeSet according to the manufacturer's instructions. Samples were cooled to 4°C, loaded into nCounter SPRINT cartridges, then analyzed using the nCounter Gene Expression Assay. Raw data were normalized by creating scaling factors for the sum of the positive controls and the geometric mean of the four housekeeping genes. Data represent the mean of normalized counts.

3.4 Statistical analysis

Data are presented as mean $\pm$ SEM. Statistical analyses were performed using SigmaPlot version 12.3. All data passed normality or equal variance tests or logarithmic transformation was used to achieve normality. Two-tailed Student's t-tests were used for analysis of data between two groups. For 2-factor analysis, a two-way ANOVA was used to analyze end-point measurements with between-group factors of pregnancy and diet, followed by Holm-Sidak for post hoc pairwise analyses. Values of $P < 0.05$ were considered to be statistically significant.

Figure 3. Experimental Design

CHAPTER 4. RESULTS

4.1 HF-feeding increases body weight and fat mass

After 8 weeks of diet feeding, HF-fed females had significantly increased body weight compared to LF-fed controls ($P<0.001$; 14A). Within HF-fed mice, the average body weight of females who eventually became pregnant was lower than those who did not become pregnant, but this was not significant ($p=0.06$). Further, HF-fed mice had increased fat mass and decreased lean mass (as percent body weight), compared to LF-fed mice $P<0.001$; Figure 4B). At study endpoint (day 18 of gestation), body weight was increased in pregnant compared to non-pregnant animals, independent of diet ($P<0.001$; and HF-fed pregnant mice had increased body weight compared to LF-fed mice ($P<0.01$, Figure 4C).

4.2 HF-feeding reduces litter size

Compared to LF-fed dams, HF-fed dams had smaller average litter size ($P<0.01$), and a greater number of resorbed pups (Table 1). There was no difference in pup body weight or placental weight in LF- compared to HF dams.

4.3 HF-feeding increases heart weight and LV mass, but is not augmented with pregnancy

In non-pregnant mice, excised heart weight was greater in HF-fed mice compared to LF-fed mice ($P<0.001$; Table 2). In LF-fed mice, heart weight was increased with pregnancy ($P<0.05$, Table 2), but HF-fed pregnant mice did not have significantly

increased heart weight compared to LF pregnant mice. Similarly, LV mass was increased with HF-feeding in non-pregnant mice ($P<0.05$, Figure 5A). However, only LF-fed mice exhibited cardiac hypertrophy with pregnancy ($P<0.001$); LV mass was not augmented with pregnancy in HF-fed mice ($p=0.221$, Figure 5A).

4.4 Wall thickness is increased in HF-compared to LF-fed pregnant mice

The increase in LV mass in NP HF-fed mice was associated with increased LV posterior wall thickness ($P<0.01$, Figure 5B). In contrast, increased LV mass with pregnancy in LF-fed mice was associated with an increase in the ventricle chamber ($P<0.001$), with no change to the wall thickness, and the diameter of the LV ventricle was significantly larger in LF- versus HF-fed pregnant mice ($P<0.05$). Thus, the relative wall thickness, a measure of LV geometry, was significantly increased in HF- compared to LF-fed mice during pregnancy ($P<0.05$, Figure 5B). Data summarizing cardiac morphology depicted in a schematic in Figure 5C.

4.5 Analysis of genes regulating metabolism in hearts

To determine the gene profile associated with changes in the cardiac structure of HF- versus LF-fed pregnant mice, we quantified mRNA abundance of 794 genes regulating metabolism involved in 34 pathways using NanoString nCounter gene expression analysis in the left ventricles of LF- and HF-fed pregnant and non-pregnant mice. Using 2-way ANOVA with pairwise comparisons, we determined that there were 47 genes with a significant effect of either gene or pregnancy with $P<0.01$. Using a p -value <0.05 , there were 26 genes with a significant effect of diet, 35 with a significant

effect of pregnancy, and 16 with a significant interaction between diet and pregnancy (Figure 6).

Since the largest number of genes with significance differences were related to fatty acid utilization, we focused our analysis on these genes. These genes are: *Acaa2*, *Acadl*, *Acox1*, *Cpt1b*, *Fabp3*, and *Ehhadh*. For *Fabp3*, there was an overall effect of diet to increase the abundance of cardiac mRNA, but no effect of pregnancy ($P < 0.01$, Figure 7F). Similarly, *Acaa2*, *Acadl*, *Acox1*, and *Cpt1b* were upregulated with HF-feeding ($P < 0.05$, Figure 7A-D). There was also a significant effect of pregnancy, but this was only significant in the LF-fed group ($P < 0.05$). Meaning, gene expression of these genes was increased in HF-fed mice (pregnant or non-pregnant), and increased in LF-fed pregnant mice, but there was no additional effect of pregnancy to increase gene expression in HF-fed pregnant mice. The expression pattern of *Ehhadh* was different, where *Ehhadh* was elevated only in the LF-fed pregnant mice ($P < 0.01$, Figure 7E). Further, the expression level of *Ehhadh* in HF-fed pregnant mice was significantly lower than that of LF-fed pregnant mice ($P < 0.05$).

Table 1: Litter size and pup/placental weights from LF- or HF-fed pregnant female mice.

Diet	Pups per litter	Pup weight (g)	Total number of resorbed pups	Number of dams with resorbed pups	Placenta weight (g)
LF	8.6 $\pm$ 0.3	1.01 $\pm$ 0.11	4	4	0.111 $\pm$ 0.005
HF	6.4 $\pm$ 0.5**	0.93 $\pm$ 0.11	21	10	0.111 $\pm$ 0.005

**, P<0.01 effect of diet

Table 2: Heart weights of LF- and HF-fed pregnant and non-pregnant female mice.

Parameter	LF		HF	
	NP (n=20)	P (n=10)	NP (n=18)	P (n=12)
<i>Mean $\pm$ SEM</i>				
Heart weight (g)	0.118 $\pm$ 0.003	0.128 $\pm$ 0.004 [#]	0.132 $\pm$ 0.003 ^{***}	0.136 $\pm$ 0.004
Heart/body weight (%)	0.529 $\pm$ 0.012	0.374 $\pm$ 0.017 ^{###}	0.412 $\pm$ 0.013 ^{***}	0.348 $\pm$ 0.016 ^{###}

***, P<0.001 effect of diet

###, P<0.001 effect of pregnancy

[#], P<0.05 effect of pregnancy

Figure 4: Weight gain from baseline to gestational day 19

A) Body weight and (B) lean and fat mass of mice fed a LF or HF diet for 8 weeks (before pregnancy). (C) Body weight of LF- and HF-fed pregnant (gestational day 19) and non-pregnant mice at study endpoint. Data are mean + SEM in n=10-20 mice per group. *, $P < 0.001$ effect of diet; #, $P < 0.001$ effect of pregnancy by 2-way ANOVA.

Figure 5: LV mass and RWT

A) LV mass and (B) relative wall thickness (RTW; 2 * posterior wall thickness divided by LV diastolic diameter) in pregnant (P) and (NP) female mice fed a low-fat (LF) or high-fat (HF) diet. Data are mean + SEM from n=20 LF NP, n=10 LF P, n=18 HF NP, and n=12 HF P. *, $P < 0.05$ compared to LF; #, $P < 0.05$ compared to NP analyzed by 2-way ANOVA followed by Holm-Sidak pairwise analysis. (C) Schematic representation depicting changes in LV chamber and wall thickness in response to diet and pregnancy. Notably, LV chamber diameter is increased with pregnancy in LF-fed mice; in contrast, HF-fed mice exhibit increased RWT with pregnancy compared to LF-fed mice.

Figure 6: Flow chart of cardiac genes measured using Nanostring significantly changed using 2-way ANOVA by either diet or pregnancy.

Figure 7: mRNA abundance of fatty acid utilization genes in pregnant and non-pregnant mice fed a LF or HF diet.

Data are expressed as counts of mRNA transcripts, normalized to the geometric mean of counts of four housekeeping genes. Data are mean + SEM from n= 8 (LF NP), n=9 (LF P), n=9 (HF NP), and n=10 (HF, P). *, P<0.05 effect of diet; **, P<0.001 effect of diet; #, P<0.05 effect of pregnancy, ##, P<0.01 effect of pregnancy by 2-way ANOVA followed by Holm-Sidak pairwise analysis.

CHAPTER 5. DISCUSSION

The present study examined the effects of obesity on cardiac hypertrophy of pregnancy in mice by quantifying left ventricular (LV) mass and the expression of genes that regulate metabolism in the hearts of pregnant obese versus lean mice. The major findings of this study are (1) HF-feeding increased body weight and fat mass in pregnant compared to non-pregnant controls, independent of diet, (2) HF-fed dams had smaller average litter sizes and a greater number of reabsorbed pups compared to LF-fed dams, (3) LF-fed mice exhibited cardiac hypertrophy in response to pregnancy; while LV mass was increased with HF-feeding, it was not further augmented with pregnancy, (4), relative wall thickness was decreased with pregnancy in LF-fed dams, and HF-fed dams had increased wall thickness compared to LF-fed dams, and (5) cardiac fatty acid utilization is increased with HF-feeding and with pregnancy, but HF- compared to LF-fed pregnant mice had decreased expression of *Ehhadh*, a gene responsible for producing medium-chain fatty acids (MCFA). These results indicate that obesity during pregnancy promotes adverse cardiac remodeling and may impair oxidation of MCFA.

This research project addresses the important concept that cardiovascular health during pregnancy may have a profound impact on lifetime maternal cardiovascular risk. We previously demonstrated that mice given a HF diet during pregnancy had augmented cardiac hypertrophy postpartum, suggesting that obesity during pregnancy is associated with elevated risk for CVD ¹². Mechanisms for obesity-mediated cardiac dysfunction are not known.

Obesity and dyslipidemia are risk factors for cardiac hypertrophy, a predictor of adverse outcomes ⁵⁶. Pregnancy, a condition of rapid weight gain and elevated serum lipid status, also induces cardiac hypertrophy, but this is not associated with CVD. We demonstrated that mice fed a LF diet during pregnancy exhibited cardiac hypertrophy. Similar to existing literature in humans ⁹ and rodents ¹⁰, this was associated with a change in cardiac geometry, where the ventricle chamber was larger and the cardiac wall thinner compared to LF non-pregnant mice. This reduction in relative wall thickness (RWT) is termed “eccentric” remodeling. In contrast, HF-fed pregnant mice did not exhibit an increase in LV mass compared to HF-fed nonpregnant mice. Further, HF-fed pregnant mice exhibited increased RWT (termed “concentric” remodeling) compared to LF-fed pregnant mice. Increased RWT and concentric remodeling, is an indicator of impaired cardiac function ¹⁶. These data suggest that HF-feeding during pregnancy promotes adverse cardiac remodeling.

Aberrant cardiac metabolism is a hallmark of disease in patients with heart failure and diabetes mellitus; the pattern of substrate utilization under these conditions is different compared to a healthy heart. Similarly, cardiac metabolism is altered under conditions of physiologic hypertrophy. The Burmese python is an animal model of extreme metabolism. Consumption of a large meal in these infrequent eaters induces a robust and striking metabolic postprandial shift. Studies by Leinwand et al reveal that the python heart grows in mass by an astonishing 40% 2-3 days following a large meal, and that this is physiological, not pathological, cardiac hypertrophy ⁵⁷. The researchers determined that cardiac metabolism following a meal was associated with markedly increased fatty acid utilization pathways, and that a composition of fatty acids in python

plasma promotes physiological cardiac growth. We likened this concept to physiologic cardiac hypertrophy during pregnancy, and wondered if changes in cardiac fatty acid utilization during pregnancy could have a protective effect against pathological cardiac growth.

Consistent with studies in *ob/ob* mice, a mouse model of genetic obesity, we report that HF-feeding increases expression of genes regulating fatty acid transport into the mitochondria (*Fabp3*, *Cpt1b*) and fatty acid β -oxidation (*Acaa2*, *Acadl*, *Acox1*). With the exception of *Fabp3*, these genes were increased with pregnancy in LF-fed mice. These data indicate that both pregnancy and obesity promote increased fatty acid utilization as a substrate in the heart, with obesity having the larger influence. However, these effects were not additive in the HF-fed pregnant mice; the mRNA count of these genes in HF-fed pregnant mice were roughly equivalent to those in the HF-fed nonpregnant mice. This suggests that obesity may “max out” fatty acid utilization through upregulation of transporters and oxidation of long- and very long-chain fatty acids. In contrast, there was one gene, *Ehhadh*, that did not follow this trend. This gene was not upregulated with HF-feeding, but was significantly upregulated with pregnancy. Notably, the expression level in the HF- pregnant mice was significantly reduced compared to that of the LF-pregnant mice. This suggests an important role for this gene in cardiac metabolism of pregnancy that was impaired with obesity. We wondered if there could be a relationship between function of *Ehhadh* and cardiac hypertrophy, and if reduction of *Ehhadh* could be associated with the adverse cardiac remodeling (i.e. thickened wall thickness) observed in the HF-fed pregnant mice.

Ehhadh encodes a protein that is part of the classical peroxisomal fatty acid β -oxidation pathway, with an essential role in the production of medium-chain dicarboxylic acids (MCDA) ⁵⁸. The purpose of MCDA production in cardiac metabolism is not known. Medium chain fatty acids (MCFA) serve as a rapid energy source because they are metabolized quickly, and it can be speculated that MCFA are an important substrate for the heart during pregnancy, when the heart's energy needs are dramatically increased. Literature reports that supplemental MCFA into the diet can improve weight loss and energy expenditure, since MCFA are preferentially utilized as fuel (versus storage in adipose tissue) ¹⁶. Studies in pregnant rats demonstrate that supplementation with MCFA, compared to LCFA, into the diet during pregnancy prevented obesity and improved lipid metabolism of offspring who were given a HF diet ⁵⁹. Thus, MCFAs have a beneficial effect on metabolism and health status.

Data from limited studies suggest a positive effect of MCFA on heart function in pathological conditions. Supplementation of MCFA improved cardiac function in rats under conditions where oxidation of fatty acids was impaired ⁶⁰. Further, MCT supplementation in the diets of rats with left ventricular hypertrophy reduced hypertrophy and cardiac oxidative stress ^{61 62}. This is an important piece of evidence, as it links MCFA supplementation with reversal of adverse cardiac remodeling. There are no studies of MCT supplementation on the heart in pregnancy. However, findings from our current study extend those of published literature by suggesting that production of MCFA is associated with normal cardiac hypertrophy of pregnancy. Taken together with the findings from python hearts that certain FA are protective in the face of extreme physiologic hypertrophy, our study describes a potential mechanism by which obesity

during pregnancy impairs a cardiac fatty acid oxidation pathway normally associated with healthy pregnancy.

In addition to aberrant cardiac hypertrophy of pregnancy, we observed other adverse effects of high fat feeding in pregnant mice. HF-fed mice had smaller litter sizes and more resorbed pups compared to LF counterparts. The last point was particularly evident during our experiment. Only 4 out of 10 pregnant LF mice had a fetal resorption, and we observed only 1 resorption per dam. In striking contrast, 10 of 12 HF dams had resorptions, and multiple resorbed fetuses were evident in many dams. We observed 21 versus only 4 total resorptions in HF versus LF mice. This is consistent with studies in humans demonstrating overweight women are more likely to have a higher incidence of infertility, miscarriage, and pregnancy complications ⁶³. For example, the rate of miscarriage in obese women is 38.1% compared to 13.3% in with normal BMI ⁶⁴. Further, Lo et al reported that as many as 78% of recurrent miscarriages are associated with obesity ⁶⁵. Taken with findings from our study, obese pregnancies carry a higher risk of pregnancy complications, adverse impacts on fetal development, and higher rate of miscarriage.

5.1 Limitations and Future Studies

There were several limitations to our study and to our data analysis. We did not characterize the cellular composition of the cardiac wall in the LF vs HF animals. Although increased RWT is nearly always associated with pathology, that was not confirmed in our study. Future studies will stain sections of the LV for fibrosis, which is a hallmark of adverse cardiac remodeling. In addition, we focused our gene analysis only

on fatty acid utilization. There were other genes pathways that were significantly altered, including genes regulating amino acid metabolism, glycolysis, and mitochondrial respiration. Impairment of these pathways are demonstrated in the literature as impaired with cardiac dysfunction. Future studies will consider interaction of multiple metabolic pathways together with fatty acid utilization as contributors to the observed pathology in the HF-fed pregnant mice.

Further, our analysis of genes regulating fatty acid utilization was global, and we did not assess other genes outside of the Nanostring CodeSet regulating MCFA oxidation. Nor did we measure fatty acid components in serum or cardiac tissue extracts. Findings from our study generated the hypothesis that production of MCFA has a protective effect on cardiac hypertrophy in pregnant mice fed a HF diet. To test this hypothesis, future studies might supplement the HF diet with a source of MFCA, such as coconut oil to see if this prevents adverse remodeling during obese pregnancy.

5.2 Public Health/Clinical Significance

Over two-thirds of the reproductive age women in the US are obese. Adverse cardiac effects during pregnancy may contribute to increased risk for CVD postpartum. Therapeutics to protect heart function during pregnancy are needed. Our results indicate that MCFA may have a protective effect on cardiac adaptation during pregnancy, which is impaired in obesity. Therefore, MCFA supplementation in the diet during pregnancy may be a preventative therapeutic to protect the heart in women with obesity. However, more research is needed to determine the fatty acid profile of hearts during pregnancy, and whether supplementation with MCFA is safe. In the meantime, women who are

obese during pregnancy should focus on consuming a well-balanced diet containing adequate lean protein sources, a variety of plant-based fats, and plenty of fresh fruits and vegetables. Additionally, the inclusion of more long chain fatty acids, such as polyunsaturated (PUFA) and mono-unsaturated fats (MUFAs), which include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) should be consumed to meet linolenic acid (ω -6; LA) and alpha linolenic acid (ω -3; ALA) requirements (LA – 11-13g/day and ALA – 1.1-1.4g/day for women ages 14 – 70 years old).^{66 67} All of which play an important role in human health and fetal development, such as reducing cardiovascular disease, inflammatory responses, and brain development.^{68 69} Sources of these essential fatty acids should be consumed from natural food sources (flax seed, chia seed, walnuts, fatty fish, seaweeds, etc.) and through a dietary supplement (i.e. DHA for vegetarians/vegans).

CHAPTER 6. CONCLUSION

In conclusion, these results demonstrate that obesity during pregnancy did not promote altered cardiac hypertrophy, however it did promote adverse cardiac remodeling in mice. While LV mass was increased with HF-feeding, there was not further augmentation with pregnancy. In contrast, HF-fed dams had increased wall thickness compared to LF-dams. Furthermore, the results also demonstrated that obesity during pregnancy decreases the expression of *Ehhadh* – a gene responsible for producing medium chain fatty acids in cardiac tissues in mice. Suggesting that the combined effects of pregnancy and obesity promote adverse remodeling and altered fatty acid utilization in the heart. The clinical significance of this study is that this study provides more evidence towards the effects of obesity during pregnancy modulating cardiac hypertrophy and altered metabolism.

REFERENCES

1. Stanley WC, Recchia FA and Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. *Physiol Rev.* 2005;85:1093-129.
2. Rich-Edwards JW, McElrath TF, Karumanchi SA and Seely EW. Breathing life into the lifecourse approach: pregnancy history and cardiovascular disease in women. *Hypertension.* 2010;56:331-4.
3. Cirillo PM and Cohn BA. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. *Circulation.* 2015;132:1234-42.
4. Chung E and Leinwand LA. Pregnancy as a cardiac stress model. *Cardiovasc Res.* 2014;101:561-70.
5. Chu SY, Bachman DJ, Callaghan WM, Whitlock EP, Dietz PM, Berg CJ, O'Keeffe-Rosetti M, Bruce FC and Hornbrook MC. Association between Obesity during Pregnancy and Increased Use of Health Care. *New England Journal of Medicine.* 2008;358:1444-1453.
6. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, Vanwagner LB and Tsao CW. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. *Circulation.* 2020;141.
7. Sanghavi M and Rutherford JD. Cardiovascular physiology of pregnancy. *Circulation.* 2014;130:1003-8.
8. Brown DW, Giles WH and Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. *American Heart Journal.* 2000;140:848-856.
9. Melchiorre K, Sharma R, Khalil A and Thilaganathan B. Maternal Cardiovascular Function in Normal Pregnancy. *Hypertension.* 2016;67:754-762.
10. Umar S, Nadadur R, Iorga A, Amjadi M, Matori H and Eghbali M. Cardiac structural and hemodynamic changes associated with physiological heart hypertrophy of pregnancy are reversed postpartum. *J Appl Physiol (1985).* 2012;113:1253-9.
11. Chung E, Haizlip KM and Leinwand LA. Pregnancy late in rodent life has detrimental effects on the heart. *Am J Physiol-Heart Circul Physiol.* 2018;315:H482-H491.
12. Che C, Dudick K and Shoemaker R. Cardiac hypertrophy with obesity is augmented after pregnancy in C57BL/6 mice. *Biol Sex Differ.* 2019;10:59.
13. Arnold AP, Cassis LA, Eghbali M, Reue K and Sandberg K. Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases. *Arterioscler Thromb Vasc Biol.* 2017;37:746-756.
14. Gori M, Lam CSP, Gupta DK, Santos ABS, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJV and Solomon SD. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. *European Journal of Heart Failure.* 2014;16:535-542.

15. Nichols FH. History of the Women's Health Movement in the 20th Century. *Journal of Obstetric, Gynecologic & Neonatal Nursing*. 2000;29:56-64.
16. Chaudhari S, Cushen SC, Osikoya O, Jaini PA, Posey R, Mathis KW and Gouloupoulou S. Mechanisms of Sex Disparities in Cardiovascular Function and Remodeling. *Compr Physiol*. 2018;9:375-411.
17. Mauvais-Jarvis F, Clegg DJ and Hevener AL. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. *Endocrine Reviews*. 2013;34:309-338.
18. Miller VM and Harman SM. An update on hormone therapy in postmenopausal women: mini-review for the basic scientist. *Am J Physiol Heart Circ Physiol*. 2017;313:H1013-H1021.
19. Miller VM and Manson JE. Women's Health Initiative Hormone Therapy Trials: New Insights on Cardiovascular Disease from Additional Years of Follow up. 2013;7:196-202.
20. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW and Paidas MJ. Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother. *Hypertension*. 2009;53:944-951.
21. Hales CM, Carroll MD, Fryar CD and Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief*. 2017:1-8.
22. Catalano PM and Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. *BMJ*. 2017;356:j1.
23. Rkhezay-Jaf J, O'Dowd JF and Stocker CJ. Maternal Obesity and the Fetal Origins of the Metabolic Syndrome. *Curr Cardiovasc Risk Rep*. 2012;6:487-495.
24. Wilson PWF, D'Agostino RB, Sullivan L, Parise H and Kannel WB. Overweight and Obesity as Determinants of Cardiovascular Risk. *Archives of Internal Medicine*. 2002;162:1867.
25. Palatini P, Reboldi G, Beilin LJ, Casiglia E, Eguchi K, Imai Y, Kario K, Ohkubo T, Pierdomenico SD, Schwartz JE, Wing L and Verdecchia P. Added predictive value of night-time blood pressure variability for cardiovascular events and mortality: the Ambulatory Blood Pressure-International Study. *Hypertension*. 2014;64:487-93.
26. Klop B, Elte JW and Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients*. 2013;5:1218-40.
27. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C and Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovascular Diabetology*. 2018;17.
28. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, Van De Sluis B, Taskinen M-R, Tokgözoğlu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ and Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*. 2017;38:2459-2472.
29. Ouchi N, Parker JL, Lugus JJ and Walsh K. Adipokines in inflammation and metabolic disease. *Nature Reviews Immunology*. 2011;11:85-97.
30. Bastien M, Poirier P, Lemieux I and Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. *Prog Cardiovasc Dis*. 2014;56:369-81.
31. Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, Nambi V, Ballantyne CM, Solomon SD, Selvin E, Folsom AR and Coresh J.

- Obesity and Subtypes of Incident Cardiovascular Disease. *J Am Heart Assoc.* 2016;5.
32. Blomstrand P, Sjoblom P, Nilsson M, Wijkman M, Engvall M, Lanne T, Nystrom FH, Ostgren CJ and Engvall J. Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain. *Cardiovasc Diabetol.* 2018;17:113.
 33. Alpert MA, Omran J and Bostick BP. Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. *Curr Obes Rep.* 2016;5:424-434.
 34. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV and Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. *JACC Heart Fail.* 2013;1:93-102.
 35. Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M and Norton GR. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. *Am J Hypertens.* 2008;21:1144-51.
 36. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC, Segerson N, Adams TD, Gress RE, Hunt SC and Litwin SE. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. *Hypertension.* 2007;49:34-9.
 37. De Simone G, Devereux RB, Chinali M, Roman MJ, Barac A, Panza JA, Lee ET and Howard BV. Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. *J Hypertens.* 2011;29:1431-8.
 38. Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, Berry JD, Khera A, McGuire DK, Vega GL, Grundy SM, de Lemos JA and Drazner MH. Relation of regional fat distribution to left ventricular structure and function. *Circ Cardiovasc Imaging.* 2013;6:800-7.
 39. Nama V, Antonios TF, Onwude J and Manyonda IT. Mid-trimester blood pressure drop in normal pregnancy: myth or reality? *J Hypertens.* 2011;29:763-8.
 40. Dennis AT, Castro JM, Ong M and Carr C. Haemodynamics in obese pregnant women. *Int J Obstet Anesth.* 2012;21:129-34.
 41. Spradley FT, Palei AC and Granger JP. Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. *Am J Physiol Regul Integr Comp Physiol.* 2015;309:R1326-43.
 42. Abdullah A, Hoq S, Choudhary R, Laifer S and Zarich S. Cardiac performance is impaired in morbidly obese pregnant females. *J Obstet Gynaecol Res.* 2012;38:258-65.
 43. Buddeberg BS, Sharma R, O'Driscoll JM, Kaelin Agten A, Khalil A and Thilaganathan B. Cardiac maladaptation in obese pregnancy at term. *Ultrasound Obstet Gynecol.* 2018.
 44. Bing RJ. The metabolism of the heart. *Harvey Lect.* 1954;50:27-70.
 45. Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, Des Rosiers C, Gerszten R, Glatz JF, Griffin JL, Gropler RJ, Holzhuetter H-G, Kizer JR, Lewandowski ED, Malloy CR, Neubauer S, Peterson LR, Portman MA, Recchia FA, Van Eyk JE and Wang TJ. Assessing Cardiac Metabolism. *Circulation Research.* 2016;118:1659-1701.
 46. Harmancey R, Wilson CR and Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. *Hypertension.* 2008;52:181-7.
 47. Fukushima A and Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. 2016;1861:1525-1534.

48. Abel ED, Litwin SE and Sweeney G. Cardiac remodeling in obesity. *Physiol Rev.* 2008;88:389-419.
49. Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, Dence C and Gropler RJ. Impact of Gender on the Myocardial Metabolic Response to Obesity. 2008;1:424-433.
50. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE and Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. *Endocrinology.* 2005;146:5341-9.
51. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JJ, Bugger H, Zaha VG and Abel ED. Mitochondrial Energetics in the Heart in Obesity-Related Diabetes: Direct Evidence for Increased Uncoupled Respiration and Activation of Uncoupling Proteins. *Diabetes.* 2007;56:2457-2466.
52. Liu LX and Arany Z. Maternal cardiac metabolism in pregnancy. *Cardiovasc Res.* 2014;101:545-53.
53. Sugden MC, Changani KK, Bentley J and Holness MJ. Cardiac glucose metabolism during pregnancy. *Biochem Soc Trans.* 1992;20:195S.
54. Williams JG, Ojaimi C, Qanud K, Zhang S, Xu X, Recchia FA and Hintze TH. Coronary nitric oxide production controls cardiac substrate metabolism during pregnancy in the dog. *Am J Physiol Heart Circ Physiol.* 2008;294:H2516-23.
55. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L and Dimitrov K. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat Biotechnol.* 2008;26:317-25.
56. Sundström J, Lind L, Vessby B, AndréN B, Aro A and Lithell HO. Dyslipidemia and an Unfavorable Fatty Acid Profile Predict Left Ventricular Hypertrophy 20 Years Later. *Circulation.* 2001;103:836-841.
57. Riquelme CA, Magida JA, Harrison BC, Wall CE, Marr TG, Secor SM and Leinwand LA. Fatty acids identified in the Burmese python promote beneficial cardiac growth. *Science.* 2011;334:528-31.
58. Houten SM, Denis S, Argmann CA, Jia Y, Ferdinandusse S, Reddy JK and Wanders RJ. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. *J Lipid Res.* 2012;53:1296-303.
59. Dong YM, Li Y, Ning H, Wang C, Liu JR and Sun CH. High dietary intake of medium-chain fatty acids during pregnancy in rats prevents later-life obesity in their offspring. *J Nutr Biochem.* 2011;22:791-7.
60. Shimojo N, Miyauchi T, Iemitsu M, Irukayama-Tomobe Y, Maeda S, Ohkubo T, Tanaka Y, Goto K and Yamaguchi I. Effects of Medium-chain Triglycerides (MCT) Application to SHR on Cardiac Function, Hypertrophy and Expression of Endothelin-1 mRNA and other Genes. *J Cardiovasc Pharmacol.* 2004;44:S181 - S185.
61. Iemitsu M, Shimojo N, Maeda S, Irukayama-Tomobe Y, Sakai S, Ohkubo T, Tanaka Y and Miyauchi T. The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations. *Am J Physiol Heart Circ Physiol.* 2008;295:H136-44.
62. Saifudeen I, Subhadra L, Konnottil R and Nair RR. Metabolic Modulation by Medium-Chain Triglycerides Reduces Oxidative Stress and Ameliorates CD36-Mediated Cardiac Remodeling in Spontaneously Hypertensive Rat in the Initial and Established Stages of Hypertrophy. 2016.

63. Dag ZO and Dilbaz B. Impact of obesity on infertility in women. *J Turk Ger Gynecol Assoc.* 2015;16:111-7.
64. Metwally M, Tuckerman E, Laird S, Ledger W and Li T. Impact of high body mass index on endometrial morphology and function in the peri-implantation period in women with recurrent miscarriage. *Reprod Biomed Online.* 2007;14:328 - 334.
65. Lo W, Rai R, Hameed A, Brailsford SR, Al-Ghamdi AA and Regan L. The effect of body mass index on the outcome of pregnancy in women with recurrent miscarriage. *J Family Community Med.* 2012;19:167-71.
66. Omega-3 Fatty Acids. 2020;2020.
67. Engel P and Yurko-Mauro K. Essential Fatty Acids - Intake Recommendations. 2010;2020.
68. Wadhwani N, Patil V and Joshi S. Maternal long chain polyunsaturated fatty acid status and pregnancy complications. *Prostaglandins Leukot Essent Fatty Acids.* 2018;136:143-152.
69. Lee HS, Barraza-Villarreal A, Biessy C, Duarte-Salles T, Sly PD, Ramakrishnan U, Rivera J, Herceg Z and Romieu I. Dietary supplementation with polyunsaturated fatty acid during pregnancy modulates DNA methylation at IGF2/H19 imprinted genes and growth of infants. *Physiol Genomics.* 2014;46:851-7.

VITA

Place of birth: Fort Wayne, Indiana

Educational institutions attended and degrees award: University of Kentucky,
Bachelor of Science

Publications: Che C, Dudick K and Shoemaker R. Cardiac hypertrophy with obesity is augmented after pregnancy in C57BL/6 mice. *Biol Sex Differ.* 2019;10:59.

Kayla Lynn Dudick